Plain-English translation of NCT07197554 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new medication called to see if it can safely and effectively treat advanced solid tumors—including Ewing sarcoma, liver cancer, and bile duct cancer. The medication works by targeting a specific protein called RBM39 that may help cancer cells survive. Researchers want to find the right dose and understand how well this treatment works.
Many advanced cancers have limited treatment options, and this medication represents a new approach that hasn't been tested in humans yet. By studying this treatment carefully, researchers hope to develop a new option for patients whose cancers haven't responded to standard therapies.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily for 5 days in a row, then take a 2-day break—this repeats in a weekly cycle. During the trial, you'll visit the clinic regularly for blood tests, imaging scans, and check-ins so doctors can monitor how you're responding and watch for any side effects. The study has about 171 participants total and is designed to find the safest and most effective dose of this medication.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States